Search - tctmd.com

Displaying 581 - 600 of 649

Sort: Relevancy | Date

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

Reusing the Radial: Repeat Transradial Access Safe and Feasible, Even Within 24 Hours

Michael O'Riordan

August 09, 2017

News Daily News

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

Leah Lawrence

August 01, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2017

Shelley Wood

July 03, 2017

News Daily News

Early Cardiology Care Tied to Better Outcomes for New A-fib Patients

Todd Neale

June 26, 2017

Podcast TCTMD Talking Points

Episode 22: The A-fib and ACS Overlap

June 14, 2017

News Daily News

Traditional Chinese Medicine May Aid in Prevention of Cardiovascular Disease

L.A. McKeown

June 12, 2017

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Daily News

Anticoagulation in Pregnant Women With Mechanical Heart Valves: A Balancing Act

Caitlin E. Cox

May 31, 2017

News Daily News

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

Todd Neale

May 11, 2017

News Daily News

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

Michael O'Riordan

May 10, 2017

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

Advertisement

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Reusing the Radial: Repeat Transradial Access Safe and Feasible, Even Within 24 Hours

How SGLT2 Inhibitors Help the Heart: Biomarker Study Offers Clues

TCTMD’s Top 10 Most Popular Stories for June 2017

Early Cardiology Care Tied to Better Outcomes for New A-fib Patients

Episode 22: The A-fib and ACS Overlap

Traditional Chinese Medicine May Aid in Prevention of Cardiovascular Disease

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

TCTMD’s Top 10 Most Popular Stories for May 2017

Anticoagulation in Pregnant Women With Mechanical Heart Valves: A Balancing Act

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

HF Survival Rates Worse Than Those of Common Cancers, Including Bladder and Breast Cancer

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content